Immunovant Stock Filter Stocks by Fundamentals
| IMVT Stock | USD 17.70 0.21 1.17% |
Immunovant's fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Immunovant Stock price.
Immunovant | Shares Owned by Institutions | Build AI portfolio with Immunovant Stock |
Immunovant ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Immunovant's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Immunovant's managers, analysts, and investors.Environmental | Governance | Social |
Immunovant Institutional Holders
Institutional Holdings refers to the ownership stake in Immunovant that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunovant's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunovant's value.| Shares | Two Seas Capital Lp | 2025-03-31 | 1.6 M | Woodline Partners Lp | 2025-03-31 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.3 M | Pictet Asset Manangement Sa | 2025-03-31 | 1.2 M | Hood River Capital Management Llc | 2025-03-31 | 1.2 M | Viking Global Investors Lp | 2025-03-31 | 1.1 M | Goldman Sachs Group Inc | 2025-03-31 | 1 M | Rock Springs Capital Management Lp | 2025-03-31 | 975.8 K | Adar1 Capital Management Llc | 2025-03-31 | 968.9 K | Fmr Inc | 2025-03-31 | 17.2 M | Deep Track Capital, Lp | 2025-03-31 | 9.5 M |
Immunovant Fundamentals
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 2.35 B | ||||
| Shares Outstanding | 171.07 M | ||||
| Shares Owned By Insiders | 58.37 % | ||||
| Shares Owned By Institutions | 55.82 % | ||||
| Number Of Shares Shorted | 20.44 M | ||||
| Price To Book | 4.33 X | ||||
| EBITDA | (437.78 M) | ||||
| Net Income | (413.84 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 98 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.48 X | ||||
| Book Value Per Share | 4.16 X | ||||
| Cash Flow From Operations | (375.87 M) | ||||
| Short Ratio | 15.71 X | ||||
| Earnings Per Share | (2.73) X | ||||
| Target Price | 43.38 | ||||
| Number Of Employees | 362 | ||||
| Beta | 0.61 | ||||
| Market Capitalization | 3.03 B | ||||
| Total Asset | 776.22 M | ||||
| Retained Earnings | (1.24 B) | ||||
| Working Capital | 698.89 M | ||||
| Net Asset | 776.22 M |
About Immunovant Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunovant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunovant using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunovant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.